Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gastrointestinal Cancers
•
Medical Oncology
How do you approach patients with lymph node only recurrences in the setting of previously resected colon cancer that are not amenable to biopsy?
Do we wait and watch vs start treatment based on ctDNA results?
Related Questions
Would you offer zolbetuximab in a non-Asian population?
In a patient with prior RT to the prostate and SVs and newly diagnosed, locally advanced rectal cancer at 10-15 cm, would you offer preoperative chemoradiation?
How long would you continue atezolizumab/bevacizumab in a patient with HCC who is having a prolonged response with stable disease?
Would you ever consider treatment without tissue diagnosis for a gastrointestinal neuroendocrine metastatic tumor based on a positive dotatate scan alone?
What systemic therapy would you use in patients with gastric cancer who had a relapse after Durva-FLOT (MATTERHORN regimen)?
Are you using Tarlatamab for neuroendocrine carcinomas (NECs) and poorly differentiated neuroencocrine tumors of GI (non-lung) origins?
In pts with HCC who initially achieved a good response on durvalumab/tremelimumab , but later lost it, would you consider rechallenging with tremelimumab ?
What is your approach for adjuvant chemotherapy for a patient with colon adenocarcinoma, pMMR, T2 with 3 positive lymph nodes and 2 pericolic adipose tumor deposits?
What are your top takeaways from ASCO GI 2025?
What adjuvant treatment would you offer a patient with adenocarcinoma of the mid-esophagus cT2N0M0 who underwent upfront esophagectomy, which showed T2N1 disease with negative margins?